Literature DB >> 1362653

Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review.

G B Baker1, R T Coutts, K F McKenna, R L Sherry-McKenna.   

Abstract

Although the non-selective monoamine oxidase inhibitors phenelzine and tranylcypromine have been used for many years, much still remains to be understood about their mechanisms of action. Other factors, in addition to the inhibition of monoamine oxidase and the subsequent elevation of brain levels of the catecholamines and 5-hydroxytryptamine, may contribute to the overall pharmacological profiles of these drugs. This review also considers the effects on brain levels of amino acids and trace amines, uptake and release of neurotransmitter amines at nerve terminals, receptors for amino acids and amines, and enzymes other than monoamine oxidase, including enzymes involved in metabolism of other drugs. The possible contributions of metabolism and stereochemistry to the actions of these monoamine oxidase inhibitors are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362653      PMCID: PMC1188458     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  78 in total

1.  Effects of low-dose 4-fluorotranylcypromine on rat brain monoamine oxidase and neurotransmitter amines.

Authors:  R L Sherry; G B Baker; R T Coutts
Journal:  Biol Psychiatry       Date:  1990-09-15       Impact factor: 13.382

2.  Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA).

Authors:  G B Baker; J T Wong; J M Yeung; R T Coutts
Journal:  J Affect Disord       Date:  1991-03       Impact factor: 4.839

3.  Differential effects of chronic antidepressants in behavioural tests of beta-adrenergic and GABAB receptor function.

Authors:  D J McManus; A J Greenshaw
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Enzymatic N-methylation of phenelzine catalyzed by methyltransferases from adrenal and other tissues.

Authors:  P H Yu; B A Davis; D A Durden
Journal:  Drug Metab Dispos       Date:  1991 Jul-Aug       Impact factor: 3.922

5.  Preferential reduction of binding of 125I-iodopindolol to beta-1 adrenoceptors in the amygdala of rat after antidepressant treatments.

Authors:  G A Ordway; C Gambarana; S M Tejani-Butt; P Areso; M Hauptmann; A Frazer
Journal:  J Pharmacol Exp Ther       Date:  1991-05       Impact factor: 4.030

6.  Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-transaminase activity in rat brain.

Authors:  D J McManus; G B Baker; I L Martin; A J Greenshaw; K F McKenna
Journal:  Biochem Pharmacol       Date:  1992-06-09       Impact factor: 5.858

7.  Tissue levels and some pharmacological properties of an acetylated metabolite of phenelzine in the rat.

Authors:  R T Coutts; A Mozayani; T J Danielson; G B Baker
Journal:  J Pharm Sci       Date:  1991-08       Impact factor: 3.534

Review 8.  Use of tryptophan in combination with other antidepressant treatments: a review.

Authors:  S N Young
Journal:  J Psychiatry Neurosci       Date:  1991-12       Impact factor: 6.186

9.  Formation of beta-phenylethylamine from the antidepressant, beta-phenylethylhydrazine.

Authors:  L E Dyck; D A Durden; A A Boulton
Journal:  Biochem Pharmacol       Date:  1985-06-01       Impact factor: 5.858

10.  Tranylcypromine stereoisomers, monoaminergic neurotransmission and behavior. A minireview.

Authors:  D F Smith
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1980-05
View more
  19 in total

Review 1.  Neurochemical and metabolic aspects of antidepressants: an overview.

Authors:  G B Baker; R T Coutts; A J Greenshaw
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

2.  The role of monoamine oxidase inhibitors in current psychiatric practice.

Authors:  Jess G Fiedorowicz; Karen L Swartz
Journal:  J Psychiatr Pract       Date:  2004-07       Impact factor: 1.325

3.  Child abuse and neglect, MAOA, and mental health outcomes: a prospective examination.

Authors:  Valentina Nikulina; Cathy Spatz Widom; Linda M Brzustowicz
Journal:  Biol Psychiatry       Date:  2011-10-25       Impact factor: 13.382

4.  The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition.

Authors:  Shahrdad Lotfipour; Monica M Arnold; Derk J Hogenkamp; Kelvin W Gee; James D Belluzzi; Frances M Leslie
Journal:  Neuropharmacology       Date:  2011-03-23       Impact factor: 5.250

Review 5.  Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.

Authors:  Kunal Nepali; Jing-Ping Liou
Journal:  J Biomed Sci       Date:  2021-04-12       Impact factor: 8.410

6.  Mitigation of sensory and motor deficits by acrolein scavenger phenelzine in a rat model of spinal cord contusive injury.

Authors:  Zhe Chen; Jonghyuck Park; Breanne Butler; Glen Acosta; Sasha Vega-Alvarez; Lingxing Zheng; Jonathan Tang; Robyn McCain; Wenpeng Zhang; Zheng Ouyang; Peng Cao; Riyi Shi
Journal:  J Neurochem       Date:  2016-05-16       Impact factor: 5.372

7.  The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors.

Authors:  Vincent Van den Eynde
Journal:  J Neural Transm (Vienna)       Date:  2021-08-09       Impact factor: 3.575

8.  β-Carbolines found in cigarette smoke elevate intracranial self-stimulation thresholds in rats.

Authors:  Andrew C Harris; Peter Muelken; Mark G LeSage
Journal:  Pharmacol Biochem Behav       Date:  2020-09-11       Impact factor: 3.533

9.  Effects of low- and high-dose tranylcypromine on [3H]tryptamine binding sites in the rat hippocampus and striatum.

Authors:  D B Goodnough; G B Baker; D D Mousseau; A J Greenshaw; W G Dewhurst
Journal:  Neurochem Res       Date:  1994-01       Impact factor: 3.996

10.  Age influences the effects of nicotine and monoamine oxidase inhibition on mood-related behaviors in rats.

Authors:  Anne-Sophie Villégier; Brittney Gallager; Jon Heston; James D Belluzzi; Frances M Leslie
Journal:  Psychopharmacology (Berl)       Date:  2010-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.